Lessons learned from clinical trials of thymic stromal lymphopoietin (TSLP) inhibition. (PubMed, J Allergy Clin Immunol) - Sep 5, 2026 - "Tezepelumab is currently the only approved anti-TSLP therapy. Other TSLP-targeting agents, including ecleralimab, SHR-1905, bosakitug, verekitug, sunakiment, TAVO101, ocankitug, HBM9378, MG-ZG122, GB-0895, and solrikitug, are in clinical development."
Journal • Review • Allergic Rhinitis • Allergy • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Chronic Rhinosinusitis With Nasal Polyps • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • Urticaria • IL13 • IL5 • TSLP
|
|
Andrew Lindsley; Christopher Brightling; Christopher S Ambrose; Emma Guttman-Yassky; Jane R Parnes; Jean Publicover; Jean-Pierre Llanos; Jonathan Corren; Joseph K Han; Joseph Spahn; Jyotsna Gulati; Lang Chen; Larry Borish; Nestor Molfino; Steven Ziegler
|